fbpx Professor Bernhard Baune on patients with mood disorders | Progress In Mind

Professor Bernhard Baune on patients with mood disorders

Our correspondent caught up with Professor Bernhard Baune of the University of Adelaide, Australia, asking him for his views on how he treats patients with mood disorders, and for his insights into new directions in both research and in patient care.

One of the most challenging parts of the treatment of patients with mood disorders is assessment. Often we look too broadly and we are not specific enough. This is especially the case in primary care but even at the tertiary care level, we are often too general. The problem is that we tend to take a symptom-orientated approach, rather than looking at the patient’s day-to-day function.

That’s not to say that symptoms aren’t important. It is necessary to improve mood but really we need to be looking to improve a patient’s function – that means improving function in the workforce, or for students, at school or university, improving learning function, as well as improving social function.

It all starts with our initial approach. As well as determining symptom severity using standard tools and structured interviews, we like to assess domains of function that span cognitive, social and workplace function.

Biomarkers and neuroimaging – part of the future

One of the hot topics in depression at the moment is identifying biomarkers. At ECNP this year there has been a lot of discussion on this. Ideally we would be able to sub-stratify patients right from the start. Currently we tend to take a backward looking view when we should be more forward thinking in terms of the patient trajectory.

There a huge initiative in Europe looking at neuroimaging markers and biomarkers. If in addition to the broad clinical assessment of the patient with depression, we had blood biomarkers and neuroimaging markers, we could combine these right at the beginning in a way that for example might help predict the likelihood of the patient experiencing future episodes of depression as well as helping inform our management decisions.

None of this is a reality in practice as yet. But we are now seeing a shift away from research that used to be very cross-sectional in its view, towards more prospective research. This is happening internationally and nationally, and across research networks and consortia. I expect in the next 5-6 years this big effort across a number of fields of research will pay off and we will be better able to stratify our patients.

Holistic approach to care

In terms of the management of patients with depression, personally I am a fan of combining psychiatric and psychotherapeutic approaches to care. And there is objective evidence that the combination of drugs and psychotherapy is better overall than drug treatment alone.

More controversial is the order in which you apply such treatments. What order or sequence – whether to combine from the outset – or whether to add one treatment to another. It may be better to start with drug treatment in order to get symptoms under control and to help the patient reach a point where they become more amenable to psychotherapy.

Time to redefine “remission”?

Of course, this leads on to how we define remission in depression. The standard tools and scales we use are a bit outdated. Our definitions of remission don’t take into consideration patient function and so are therefore not helpful.

In fact I don’t like the word “remission”. We need to be looking at defining our treatment success with function in mind.

There is a correlation between improvements in mood and improvements in cognition in depression, but about a third of patients experience an alleviation of mood without any change in cognitive function.

We need to assess the deficits in the first place and to look, with the patient, at what they’d like to achieve. Then we can develop a treatment strategy that combines pharmacological and non-pharmacological treatments. This means using antidepressant therapies. I would never use agents that are specifically indicated for treating cognitive deficits, or agents indicated in ADHD for example in these patients. I’d be looking to use antidepressants based on evidence of effects on both cognition and mood. Then in my practice I’d want to define a programme of non-pharmacological interventions, designed to improve cognitive function and encompassing physical activity and life style changes.

Disclaimers: The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente ai Professionisti Sanitari. I contenuti di questo sito sono prodotti da un team dedicato di Professionisti Sanitari e medical writer il cui obiettivo è presentare le novità scientifiche più recenti insieme ad opinioni di esperti ed approfondimenti in ambito psichiatrico e neurologico. Per poter accedere al sito è, quindi, necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Professionista Sanitario.
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country